Patents by Inventor Marina Konopleva

Marina Konopleva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR
    Publication number: 20230135992
    Abstract: The present invention relates to combination therapy with a mutant IDH inhibitor of Formula (I) and a Bcl-2 inhibitor, for the treatment of cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: May 4, 2023
    Inventors: Nathan Arthur BROOKS, Courtney DINARDO, Raymond GILMOUR, Marina KONOPLEVA, Vivian SALAMA
  • COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20220016118
    Abstract: A combination of (a) Midostaurin, or a pharmaceutically acceptable salt thereof, or a complex thereof, or a co-crystal thereof, or a solvate, including hydrate, thereof, and (b) a Mcl-1 inhibitor and compositions and uses thereof.
    Type: Application
    Filed: November 14, 2019
    Publication date: January 20, 2022
    Inventors: Ensar HALILOVIC, Youzhen WANG, Erick MORRIS, Marina KONOPLEVA, Anna SKWARSKA
  • COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20210169865
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 10, 2021
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
    Patent number: 10959993
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20180303815
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Application
    Filed: November 3, 2016
    Publication date: October 25, 2018
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • CDDO-compounds and combination therapies thereof
    Patent number: 7795305
    Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: September 14, 2010
    Assignees: Board of Regents, The University of Texas System, The Trustees of Dartmouth College
    Inventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn
  • Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex
    Publication number: 20100173928
    Abstract: In certain aspects, the invention relates to methods for identifying compounds which modulate Akt activity mediated by the rictor-mTOR complex and methods for treating or preventing a disorder that is associated with aberrant Akt activity.
    Type: Application
    Filed: July 15, 2008
    Publication date: July 8, 2010
    Inventors: David M. Sabatini, Dos D. Sarbassov, Michael Andreeff, Marina Konopleva, Zhihong Zeng, Francis J. Giles
  • CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF
    Publication number: 20090093447
    Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
    Type: Application
    Filed: October 10, 2008
    Publication date: April 9, 2009
    Inventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn
  • COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE
    Publication number: 20090048205
    Abstract: The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 19, 2009
    Inventors: Colin Meyer, Michael Andreeff, Marina Konopleva, Robert M. Kral, JR.
  • CDDO-compounds and combination therapies thereof
    Patent number: 7435755
    Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: October 14, 2008
    Assignees: The Trustees of Dartmouth College, Board of Regents, The University of Texas System
    Inventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn
  • CDDO-compounds and combination therapies thereof
    Publication number: 20030119732
    Abstract: CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
    Type: Application
    Filed: November 28, 2001
    Publication date: June 26, 2003
    Applicant: Board of
    Inventors: Marina Konopleva, Michael Andreeff, Michael B. Sporn